Outcomes of Salvage Radical Prostatectomy for M0 Castration-resistant Recurrent Prostate Cancer: A Reasonable Option in the Era of New Antiandrogen Therapies?
Tài liệu tham khảo
Loriot, 2018, Management of non-metastatic castrate-resistant prostate cancer: a systematic review, Cancer Treat Rev, 70, 223, 10.1016/j.ctrv.2018.09.006
Smith, 2005, Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer, J Clin Oncol, 23, 2918, 10.1200/JCO.2005.01.529
Smith, 2018, Apalutamide treatment and metastasis-free survival in prostate cancer, N Engl J Med, 378, 1408, 10.1056/NEJMoa1715546
Hussain, 2018, Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer, N Engl J Med, 378, 2465, 10.1056/NEJMoa1800536
Gontero, 2019, Salvage radical prostatectomy for recurrent prostate cancer: morbidity and functional outcomes from a large multicenter series of open versus robotic approaches, J Urol, 202, 725, 10.1097/JU.0000000000000327
Heidenreich, 2015, The role of palliative surgery in castration-resistant prostate cancer, Oncol Res Treat, 38, 670, 10.1159/000442268